Zeto has built out a three-device portfolio spanning outpatient, ICU/ED, and home settings, each FDA-cleared, rather than pursuing a single hardware SKU, giving it commercial breadth uncommon at Series B. Its dry-electrode setup competes on deployment speed and staffing constraints rather than diagnostic novelty, positioning it against workflow-focused rivals like Ceribell more than against foundation-model diagnostics plays like BioSerenity.